The Phase 2b SEISMiC Extension Study showed istaroxime significantly improved systolic blood pressure over six hours compared to placebo. Windtree plans to present detailed study findings, including ...
Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a ...
AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...
Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at ...
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo. The study ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ...
Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback